326 related articles for article (PubMed ID: 22829268)
1. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial.
Mori E; Ikeda M; Kosaka K;
Ann Neurol; 2012 Jul; 72(1):41-52. PubMed ID: 22829268
[TBL] [Abstract][Full Text] [Related]
2. Increased plasma donepezil concentration improves cognitive function in patients with dementia with Lewy bodies: An exploratory pharmacokinetic/pharmacodynamic analysis in a phase 3 randomized controlled trial.
Mori E; Ikeda M; Nakai K; Miyagishi H; Nakagawa M; Kosaka K
J Neurol Sci; 2016 Jul; 366():184-190. PubMed ID: 27288803
[TBL] [Abstract][Full Text] [Related]
3. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
Rolinski M; Fox C; Maidment I; McShane R
Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
[TBL] [Abstract][Full Text] [Related]
4. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.
Gauthier S; Feldman H; Hecker J; Vellas B; Emir B; Subbiah P;
Curr Med Res Opin; 2002; 18(6):347-54. PubMed ID: 12442882
[TBL] [Abstract][Full Text] [Related]
5. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
Rogers SL; Doody RS; Mohs RC; Friedhoff LT
Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
[TBL] [Abstract][Full Text] [Related]
6. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.
Feldman H; Gauthier S; Hecker J; Vellas B; Subbiah P; Whalen E;
Neurology; 2001 Aug; 57(4):613-20. PubMed ID: 11524468
[TBL] [Abstract][Full Text] [Related]
7. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.
Thomas AJ; Burn DJ; Rowan EN; Littlewood E; Newby J; Cousins D; Pakrasi S; Richardson J; Sanders J; McKeith IG
Int J Geriatr Psychiatry; 2005 Oct; 20(10):938-44. PubMed ID: 16163744
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study.
Ikeda M; Mori E; Kosaka K; Iseki E; Hashimoto M; Matsukawa N; Matsuo K; Nakagawa M;
Dement Geriatr Cogn Disord; 2013; 36(3-4):229-41. PubMed ID: 23949147
[TBL] [Abstract][Full Text] [Related]
10. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia.
Minett TS; Thomas A; Wilkinson LM; Daniel SL; Sanders J; Richardson J; Littlewood E; Myint P; Newby J; McKeith IG
Int J Geriatr Psychiatry; 2003 Nov; 18(11):988-93. PubMed ID: 14618549
[TBL] [Abstract][Full Text] [Related]
11. Donepezil for vascular cognitive impairment.
Malouf R; Birks J
Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
[TBL] [Abstract][Full Text] [Related]
12. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial.
Black S; Román GC; Geldmacher DS; Salloway S; Hecker J; Burns A; Perdomo C; Kumar D; Pratt R;
Stroke; 2003 Oct; 34(10):2323-30. PubMed ID: 12970516
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.
Farlow MR; Salloway S; Tariot PN; Yardley J; Moline ML; Wang Q; Brand-Schieber E; Zou H; Hsu T; Satlin A
Clin Ther; 2010 Jul; 32(7):1234-51. PubMed ID: 20678673
[TBL] [Abstract][Full Text] [Related]
16. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.
Dubois B; Tolosa E; Katzenschlager R; Emre M; Lees AJ; Schumann G; Pourcher E; Gray J; Thomas G; Swartz J; Hsu T; Moline ML
Mov Disord; 2012 Sep; 27(10):1230-8. PubMed ID: 22915447
[TBL] [Abstract][Full Text] [Related]
17. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.
Aarsland D; Laake K; Larsen JP; Janvin C
J Neurol Neurosurg Psychiatry; 2002 Jun; 72(6):708-12. PubMed ID: 12023410
[TBL] [Abstract][Full Text] [Related]
18. The effects of donepezil in Alzheimer's disease - results from a multinational trial.
Burns A; Rossor M; Hecker J; Gauthier S; Petit H; Möller HJ; Rogers SL; Friedhoff LT
Dement Geriatr Cogn Disord; 1999; 10(3):237-44. PubMed ID: 10325453
[TBL] [Abstract][Full Text] [Related]
19. Increased dosage of donepezil for the management of behavioural and psychological symptoms of dementia in dementia with Lewy bodies.
Manabe Y; Ino T; Yamanaka K; Kosaka K
Psychogeriatrics; 2016 May; 16(3):202-8. PubMed ID: 26179411
[TBL] [Abstract][Full Text] [Related]
20. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials.
Román GC; Wilkinson DG; Doody RS; Black SE; Salloway SP; Schindler RJ
Dement Geriatr Cogn Disord; 2005; 20(6):338-44. PubMed ID: 16192723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
